Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.

Details

Language :

English

ISSN :

15228517

Volume :

25

Issue :

8

Database :

Complementary Index

Journal :

Neuro-Oncology

Publication Type :

Academic Journal

Accession number :

169792752

Full Text :

https://doi.org/10.1093/neuonc/noad085